IonQ Snubbed by $2 Billion Federal Quantum Fund, Yet Institutions Pile In and Stock Rallies 129%

IonQ stock rose 3% on missing $2B CHIPS funding; shares up 128.9% since April. Short interest high (22%) but institutions buy on 755% revenue growth, $3.3B cash.

The US Department of Commerce handed out just over $2 billion in CHIPS Act funding to nine quantum computing players on May 27, 2026 – and IonQ was not among the recipients. IBM scooped up a full $1 billion for its “Anderon” quantum chip factory, while D-Wave, Rigetti, and Infleqtion each landed roughly $100 million. IonQ got nothing. Yet the stock gained 3% that day to $65.56, and the move was no fluke: since April 1, shares have surged 128.9%, dwarfing the S&P 500’s 14.4% advance over the same stretch.

The rally has unfolded even as short sellers circle. Between 20.7% and 22.4% of IonQ’s freely traded shares are sold short – a level that normally signals deep skepticism among professionals. Institutional ownership stands at 41.4%, with holdings concentrated among a handful of heavyweight asset managers. In the fourth quarter alone, Vanguard Group boosted its position by 18.5%, snapping up an additional 5.4 million shares to reach 34.7 million shares worth roughly $1.56 billion. State Street Corp raised its stake by 19.9% in the third quarter to 6.3 million shares ($387.4 million). ProShare Advisors added 30.3%, and Lansdowne Partners UK surged 286.1% to 1.9 million shares. Clear Street Group entered as a new investor with a $61.5 million position.

The institutional buying spree appears to be betting on fundamentals that overshadow the federal snub. IonQ’s first-quarter 2026 revenue hit $64.67 million – a 755% jump from a year earlier and well above analyst estimates of roughly $50 million. But the bottom line disappointed: the company reported a loss per share of $0.34, worse than the expected $0.26 deficit. For the full year, management lifted its revenue forecast to a range of $260 million to $270 million. The order backlog sits at $470 million, and the company holds a cash pile of approximately $3.3 billion, a cushion that B. Riley analysts highlight as a key strength.

That liquidity is reinforced by ongoing contracts, including one with the Defense Advanced Research Projects Agency (DARPA). Sentiment around possible government involvement remains elevated: on the prediction platform Kalshi, traders assign a 32% probability that IonQ will receive a direct government equity stake in 2026. Broader speculation about a national quantum push has helped buoy the stock, even as the CHIPS Act cash went elsewhere.

Of the 17 analysts covering IonQ, ten rate it a buy, six say hold, and one recommends selling. The average price target sits near $69. Zacks Investment Research, however, assigns a sell rating, citing the stretched valuation and ongoing losses. IonQ’s technology uses trapped ions, and the company claims a two-qubit gate fidelity of 99.99% – a metric it touts as superior to superconducting and neutral atom approaches. That technical edge, combined with a $3.3 billion war chest and a soaring revenue base, has convinced some institutions to look past the missing $2 billion handout and double down on the long-term story.